pembrolizumab at cytolytic synapse; biopsy-revealed molecular profile, addressing throughput drop
pembrolizumab (pd1 brake release) acts at the cytolytic synapse; biopsy-revealed molecular profile step of the cancer-immunity cycle. The failure mode is throughput drop: factory's rate of work falls. Fewer units produced per unit time. Bottleneck somewhere on the production line.
What this is
The Living Scorecard is Encounter's open record of structural predictions. Each hypothesis names a candidate intervention, where in the cycle it is predicted to act, the failure mode it is predicted to address, and the evidence available when the prediction was made.
Predictions are locked with timestamps before they can be tested. Encounter generates them daily, many more than any one person can chase, so the field can see what the framework claims structurally, ahead of the data. Some will hold. Some will be refuted. Both stay on the page. The point is that each prediction is committed before the answer is known, so the data that arrives later can confirm or refute it.
Structural argument
At the cytolytic synapse; biopsy-revealed molecular profile step of the cancer-immunity cycle (reactor regime, position P10), pembrolizumab acts via pd1 brake release. The failure mode is throughput drop: factory's rate of work falls. Fewer units produced per unit time. Bottleneck somewhere on the production line. The intervention's regime-type class lines up with the position's regime, and failure_throughput_drop belongs to that regime's failure set.
rule_r13(required) — Combinatorial candidate is grounded in R13's position-to-state table, which determines which interventions are structurally addressable at which positions.
Substrate
- Domain
- domain_cellular_biology
- Cycle
- cycle_l4_canonical
- Position(s)
- position_p10
- Failure modes
- failure_throughput_drop
Evidence at generation
"pembrolizumab" AND "cancer immunotherapy"
- PMID 30886395
Immunotherapy in colorectal cancer: rationale, challenges and potential.
- PMID 28801472
Breast Cancer Immunotherapy: Facts and Hopes.
- PMID 35810989
Colorectal cancer immunotherapy-Recent progress and future directions.
- PMID 39342430
PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders.
- PMID 36483562
Predictive biomarkers of colon cancer immunotherapy: Present and future.
Targets: CHEMBL3307223
inhibitor
pembrolizumab cancer immunotherapy
- NCT03867084
Hepatocellular Carcinoma
Primary: Recurrence-Free Survival (RFS)
- NCT04920617
Relapsed Diffuse Large B-cell Lymphoma
Primary: Objective response rate (ORR) in each of the study arms
- NCT03050060
Metastatic Kidney Carcinoma
Primary: Response Rate
- NCT04198766
Solid Tumor
Primary: Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
- NCT05691829
NSCLC Stage IV
Primary: Percent of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by End of Treatment Cycle 4
Status timeline
- Draft2026-05-30T11:27:14Z
Generated by combinatorial walker (v0.1.1; verb_target-aware, sub-regime failures). Awaiting operator review for the daily top-5 batch.
by system